20 Years of Investing in ME Research to Discover ME: In Pursuit of the Mechanisms and Treatment Strategies for Myalgic Encephalomyelitis
#BRMEC15
Keynote Speech at #BRMEC15
The 15th International Biomedical Research into ME Colloquium takes place at the Wellcome Genome Campus, UK, during 27-29 May. The #BRMEC15 colloquium brings together leading international scientists and clinicians focused on sharing knowledge and collaborating to advance knowledge regarding the pathogenesis and aetiology of ME.
We are delighted to announce that Professor Sarah Teichmann will be giving the keynote speech at the upcoming colloquium.
BRMEC15 Colloquium to Feature Professor Sarah Teichmann
The Invest in ME Research (IiMER) BRMEC15 Colloquium is pleased to announce
that Professor Sarah Teichmann, a leading figure in genomics and single-cell biology, will deliver
the keynote address at this year’s meeting. The invitation-only colloquium brings together researchers from across Europe
and internationally to share the latest insights into Myalgic Encephalomyelitis (ME) and long COVID research.
Her keynote at BRMEC15 represents a great opportunity for the ME research community.
A recurring obstacle in ME research
is the difficulty of looking beyond peripheral blood to where disease may actually be driven — in tissues, organs, and systems
that standard sampling cannot reach. Professor Teichmann's work on the Human Cell Atlas and single-cell transcriptomics addresses
this problem directly, offering tools and frameworks for identifying molecular pathways from genetic risk variants through to
therapeutic targets — precisely what the ME field needs to accelerate its transition from hypothesis to treatment.
Hearing from the scientist who pioneered this approach, in a focused and collaborative setting, is a rare and compelling reason
to attend.
Professor Sarah Teichmann
Professor Teichmann is Professor of Stem Cell Medicine at the University of Cambridge and Senior Research Fellow
of Churchill College, Cambridge.
She is widely recognised as co-founder and co-leader of the Human Cell Atlas,
a global initiative mapping all
human cell types, and for her pioneering work in single-cell transcriptomics.
Her research combines computational
and experimental approaches to understand cell identity,
gene regulation, and immune system function, providing tools and frameworks that are widely applied across biomedical
research.
Professor Teichmann has received multiple awards for her contributions to genomics and systems biology —
including the Lister Prize, the Biochemical Society Colworth Medal, the Royal Society Crick Lecture,
the EMBO Gold Medal, and the Mary Lyon Medal — and serves on several international advisory boards,
bringing both scientific rigour and collaborative leadership to the field. She is also currently Vice President
of Translational
Research at GlaxoSmithKline (GSK), reflecting the breadth of her impact across both academic and industry settings.
BRMEC Colloquia: Advancing ME Research Through Collaboration
The BRMEC series of colloquia, organised by Invest in ME Research, is designed to foster the exchange of new expertise and innovation in the study of ME. By bringing together leading scientists from the UK, Europe, and beyond, the meetings provide a secure, invitation-only environment where current and emerging research can be shared, including unpublished data. Each session, including Post-Genomics, Systems Biology, Chronic Infection, Neuroscience, Immunology, and Metabolism, aims to identify actionable pathways, define molecular subgroups, and guide future study designs. In line with the charity’s ethos, BRMEC15 emphasises collaboration, data integration, and methodological rigour, ensuring that researchers are equipped to move the field forward with both practical insights and high-quality scientific evidence.
